Structural insights into the binding of zoledronic acid with RANKL via computational simulations

Zoledronic acid (ZOL) inhibits receptor activator of nuclear factor-κB ligand (RANKL) and reduces bone turnover. This plays an important role in the development of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Previous reports have shown that ZOL binds to the enzyme farnesyl pyrophosphate...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ruijie, Zhang, Wenjie, Ma, Hailong, Zou, Duohong, Zhang, Zhiyuan, Wang, Shaoyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527314/
https://www.ncbi.nlm.nih.gov/pubmed/36200071
http://dx.doi.org/10.3389/fmolb.2022.992473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527314/
https://www.ncbi.nlm.nih.gov/pubmed/36200071
http://dx.doi.org/10.3389/fmolb.2022.992473

Ejemplares similares